Format

Send to

Choose Destination
Bull Cancer. 2004 Feb;91(2):167-71.

[Docetaxel and squamous cell carcinoma of the head and neck].

[Article in French]

Author information

1
Clinique d'oncologie et radiothérapie, Hôpital Bretonneau, 2, bd Tonnellé, 37044 Tours. calais@med.univ-tours.fr

Abstract

Chemotherapy in head and neck carcinoma is used as palliative treatment but also as induction treatment or combined treatment with concurrent radiation therapy. Platinum and 5-fluorouracil are the most commonly used cytotoxic agents. Docetaxel is an active drug for treating head and neck carcinoma. For patients with recurrent or metastatic disease, docetaxel could be used either as a second line chemotherapy or a first line for patients who received previously platinum or 5FU. In combination with platinum and 5FU, used as induction chemotherapy the TPF regimen is a very active treatment with an overall response rate of 85 to 90% with a manageable acute toxicity rate. This approach is under investigation in terms of ability to obtain more larynx preservation compared to the standard approach with platinum and 5FU. Docetaxel is a radiosensitizer. Concurrent radiochemotherapy using docetaxel alone is feasible, Trials are needed to define the optimal regimen for combining radiation, platinum and docetaxel.

PMID:
15047456
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center